Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

The results could pave the way for Pfizer's drug ponsegromab to become the first-ever approved treatment specifically for ...

Inspired by Pfizer’s response to the COVID pandemic, Miguel Agreda ’25 brought his skills as a joint-degree MBA/MPH student ...

An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...

Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.

KP.2-adapted COVID-19 vaccine received FDA approval. Manufacturing Optimization Program aims to deliver $1.5b in savings by ...

Pfizer announced the appointment of Amr Seif as the Cluster Lead for Egypt, Levant, and Iraq (ELI) and Country Manager for ...